Long-Term Effectiveness of Oral Ferric Maltol vs Intravenous Ferric Carboxymaltose for the Treatment of Iron-Deficiency Anemia in Patients With Inflammatory Bowel Disease: A Randomized Controlled Noninferiority Trial (vol 28, pg 373, 2022)


Por: Howaldt, S, Domenech, E, Martinez, N, Schmidt, C and Bokemeyer, B

Publicada: 2 mar 2022
Resumen:


Filiaciones:
Howaldt, S:
 Res Inst IBD HaFCED eK, Hamburg, Germany

:
 Hosp Badalona Germans Trias & Pujol, Dept Gastroenterol & Hepatol, Badalona, Spain

 Ctr Invest Biomed Red Enfermedades Hepat & Digest, Badalona, Spain

Martinez, N:
 Gastroenterol Res Amer, San Antonio, TX USA

Schmidt, C:
 Klinikum Fulda, Dept Gastroenterol Hepatol Endocrinol Diabetol &, Fulda, Germany

Bokemeyer, B:
 Univ Hosp Schleswig Holstein, Gastroenterol Practice Minden, Clin Internal Med 1, Campus Kiel, Kiel, Germany

 Univ Hosp Schleswig Holstein, Clin Internal Med 1, Campus Kiel, Kiel, Germany
ISSN: 10780998





Inflammatory Bowel Diseases
Editorial
Lippincott Williams & Wilkins Ltd., JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA, Estados Unidos America
Tipo de documento: Correction
Volumen: 28 Número: 3
Páginas: 494-494
WOS Id: 000763011200029
ID de PubMed: 34612489
imagen hybrid, Green Published

MÉTRICAS